Literature DB >> 28676499

Kinetic and structural analyses reveal residues in phosphoinositide 3-kinase α that are critical for catalysis and substrate recognition.

Sweta Maheshwari1, Michelle S Miller2, Robert O'Meally3, Robert N Cole3, L Mario Amzel4, Sandra B Gabelli5,2,6.   

Abstract

Phosphoinositide 3-kinases (PI3Ks) are ubiquitous lipid kinases that activate signaling cascades controlling cell survival, proliferation, protein synthesis, and vesicle trafficking. PI3Ks have dual kinase specificity: a lipid kinase activity that phosphorylates the 3'-hydroxyl of phosphoinositides and a protein-kinase activity that includes autophosphorylation. Despite the wealth of biochemical and structural information on PI3Kα, little is known about the identity and roles of individual active-site residues in catalysis. To close this gap, we explored the roles of residues of the catalytic domain and the regulatory subunit of human PI3Kα in lipid and protein phosphorylation. Using site-directed mutagenesis, kinetic assays, and quantitative mass spectrometry, we precisely mapped key residues involved in substrate recognition and catalysis by PI3Kα. Our results revealed that Lys-776, located in the P-loop of PI3Kα, is essential for the recognition of lipid and ATP substrates and also plays an important role in PI3Kα autophosphorylation. Replacement of the residues His-936 and His-917 in the activation and catalytic loops, respectively, with alanine dramatically changed PI3Kα kinetics. Although H936A inactivated the lipid kinase activity without affecting autophosphorylation, H917A abolished both the lipid and protein kinase activities of PI3Kα. On the basis of these kinetic and structural analyses, we propose possible mechanistic roles of these critical residues in PI3Kα catalysis.
© 2017 by The American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  ATP; lipid kinase; p110a; p110ap85a; phosphatidylinositide 3-kinase (PI 3-kinase); phosphoinositide; protein kinase; serine/threonine protein kinase

Mesh:

Substances:

Year:  2017        PMID: 28676499      PMCID: PMC5566514          DOI: 10.1074/jbc.M116.772426

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  47 in total

Review 1.  From the bench to the bed side: PI3K pathway inhibitors in clinical development.

Authors:  Saveur-Michel Maira; Peter Finan; Carlos Garcia-Echeverria
Journal:  Curr Top Microbiol Immunol       Date:  2010       Impact factor: 4.291

Review 2.  Protein kinase biochemistry and drug discovery.

Authors:  Phillip A Schwartz; Brion W Murray
Journal:  Bioorg Chem       Date:  2011-08-03       Impact factor: 5.275

3.  Frequent mutation of the PIK3CA gene in ovarian and breast cancers.

Authors:  Douglas A Levine; Faina Bogomolniy; Cindy J Yee; Alex Lash; Richard R Barakat; Patrick I Borgen; Jeff Boyd
Journal:  Clin Cancer Res       Date:  2005-04-15       Impact factor: 12.531

4.  Deletion and site-directed mutagenesis of the ATP-binding motif (P-loop) in the bifunctional murine ATP-sulfurylase/adenosine 5'-phosphosulfate kinase enzyme.

Authors:  A T Deyrup; S Krishnan; B N Cockburn; N B Schwartz
Journal:  J Biol Chem       Date:  1998-04-17       Impact factor: 5.157

5.  Mutation of the PIK3CA gene in ovarian and breast cancer.

Authors:  Ian G Campbell; Sarah E Russell; David Y H Choong; Karen G Montgomery; Marianne L Ciavarella; Christine S F Hooi; Briony E Cristiano; Richard B Pearson; Wayne A Phillips
Journal:  Cancer Res       Date:  2004-11-01       Impact factor: 12.701

6.  Effects of oncogenic p110alpha subunit mutations on the lipid kinase activity of phosphoinositide 3-kinase.

Authors:  Jeffrey D Carson; Glenn Van Aller; Ruth Lehr; Robert H Sinnamon; Robert B Kirkpatrick; Kurt R Auger; Dashyant Dhanak; Robert A Copeland; Richard R Gontarek; Peter J Tummino; Lusong Luo
Journal:  Biochem J       Date:  2008-01-15       Impact factor: 3.857

7.  Crystal structure of the catalytic subunit of cAMP-dependent protein kinase complexed with MgATP and peptide inhibitor.

Authors:  J Zheng; D R Knighton; L F ten Eyck; R Karlsson; N Xuong; S S Taylor; J M Sowadski
Journal:  Biochemistry       Date:  1993-03-09       Impact factor: 3.162

8.  Oncogenic mutations of PIK3CA in human cancers.

Authors:  Yardena Samuels; Victor E Velculescu
Journal:  Cell Cycle       Date:  2004-10-12       Impact factor: 4.534

9.  Vps34p required for yeast vacuolar protein sorting is a multiple specificity kinase that exhibits both protein kinase and phosphatidylinositol-specific PI 3-kinase activities.

Authors:  J H Stack; S D Emr
Journal:  J Biol Chem       Date:  1994-12-16       Impact factor: 5.157

10.  Autophosphorylation of serine 608 in the p85 regulatory subunit of wild type or cancer-associated mutants of phosphoinositide 3-kinase does not affect its lipid kinase activity.

Authors:  Meredith J Layton; Mirette Saad; Nicole L Church; Richard B Pearson; Christina A Mitchell; Wayne A Phillips
Journal:  BMC Biochem       Date:  2012-12-27       Impact factor: 4.059

View more
  14 in total

1.  Double PIK3CA mutations in cis increase oncogenicity and sensitivity to PI3Kα inhibitors.

Authors:  Pedram Razavi; Jared L Johnson; Hong Shao; Neil Vasan; Hardik Shah; Alesia Antoine; Erik Ladewig; Alexander Gorelick; Ting-Yu Lin; Eneda Toska; Guotai Xu; Abiha Kazmi; Matthew T Chang; Barry S Taylor; Maura N Dickler; Komal Jhaveri; Sarat Chandarlapaty; Raul Rabadan; Ed Reznik; Melissa L Smith; Robert Sebra; Frauke Schimmoller; Timothy R Wilson; Lori S Friedman; Lewis C Cantley; Maurizio Scaltriti; José Baselga
Journal:  Science       Date:  2019-11-08       Impact factor: 47.728

2.  Therapeutic implications of activating noncanonical PIK3CA mutations in head and neck squamous cell carcinoma.

Authors:  Nan Jin; Bhumsuk Keam; Janice Cho; Michelle J Lee; Hye Ryun Kim; Hayarpi Torosyan; Natalia Jura; Patrick Ks Ng; Gordon B Mills; Hua Li; Yan Zeng; Zohar Barbash; Gabi Tarcic; Hyunseok Kang; Julie E Bauman; Mi-Ok Kim; Nathan K VanLandingham; Danielle L Swaney; Nevan J Krogan; Daniel E Johnson; Jennifer R Grandis
Journal:  J Clin Invest       Date:  2021-11-15       Impact factor: 14.808

3.  Class I PI3K Biology.

Authors:  Tihitina Y Aytenfisu; Hannah M Campbell; Mayukh Chakrabarti; L Mario Amzel; Sandra B Gabelli
Journal:  Curr Top Microbiol Immunol       Date:  2022       Impact factor: 4.737

4.  Modeling Kaempferol as a Potential Pharmacological Agent for COVID-19/PF Co-Occurrence Based on Bioinformatics and System Pharmacological Tools.

Authors:  Yong Jiang; Yi-Zi Xie; Chen-Wen Peng; Kai-Nan Yao; Xue-Ying Lin; Shao-Feng Zhan; Hong-Fa Zhuang; Hui-Ting Huang; Xiao-Hong Liu; Xiu-Fang Huang; Hang Li
Journal:  Front Pharmacol       Date:  2022-06-08       Impact factor: 5.988

Review 5.  At a crossroads: how to translate the roles of PI3K in oncogenic and metabolic signalling into improvements in cancer therapy.

Authors:  Neil Vasan; Lewis C Cantley
Journal:  Nat Rev Clin Oncol       Date:  2022-04-28       Impact factor: 65.011

Review 6.  Diacylglycerol kinases: Relationship to other lipid kinases.

Authors:  Qianqian Ma; Sandra B Gabelli; Daniel M Raben
Journal:  Adv Biol Regul       Date:  2018-09-28

7.  Allosteric Activation of PI3Kα Results in Dynamic Access to Catalytically Competent Conformations.

Authors:  Mayukh Chakrabarti; Sandra B Gabelli; L Mario Amzel
Journal:  Structure       Date:  2020-02-10       Impact factor: 5.006

8.  Structural Features that Distinguish Inactive and Active PI3K Lipid Kinases.

Authors:  Mingzhen Zhang; Hyunbum Jang; Ruth Nussinov
Journal:  J Mol Biol       Date:  2020-09-10       Impact factor: 5.469

Review 9.  Inositol phosphate kinases: Expanding the biological significance of the universal core of the protein kinase fold.

Authors:  Stephen B Shears; Huanchen Wang
Journal:  Adv Biol Regul       Date:  2018-10-27

10.  Elaborating piperazinyl-furopyrimidine based scaffolds as phosphoinositol-3-kinase enzyme alpha (PI3Kα) inhibitors to combat pancreatic cancer.

Authors:  Mai A Mansour; Deena S Lasheen; Hatem M Gaber; Khaled A M Abouzid
Journal:  RSC Adv       Date:  2020-08-28       Impact factor: 4.036

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.